Zealand Pharma AS
(OCSE:ZEAL)
kr
730
0 (0%)
Market Cap: 51.57 Bil
Enterprise Value: 43.49 Bil
PE Ratio: 0
PB Ratio: 5.83
GF Score: 67/100 Zealand Pharma A/S at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023 / 11:40PM GMT
Release Date Price:
kr276
(-0.07%)
Rajan Sharma
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good afternoon, everyone. My name is Rajan Sharma. I'm a European Biotech analyst here at Goldman Sachs. Thanks for those of you in the room for making it through to the last session of the day. And pleased that we have Adam Steensberg, who's the CEO of Zealand Pharma, with us this afternoon. Adam, thank you for joining us. And again, thanks for fighting through the jet lag.
Adam Sinding Steensberg;S;President;CEO
Zealand Pharma A
/-&
Thanks for the invitation. Happy to be here.
Questions & Answers
Rajan Sharma;Adam Sinding Steensberg<
Goldman Sachs Group, Inc., Research Division - Research Analyst
So I guess maybe we'll just start on a high level and you've been in the CEO seat for just over a year or so now at Zealand. So do you want to kind of run us through where the company is versus when you first started and kind of key changes over the last 12 months?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot